Biol Reprod Lalor Postdoctoral Fellowships -- Application Deadline January 15, 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moger, W. H.
Right arrow Articles by Murphy, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moger, W. H.
Right arrow Articles by Murphy, P. R.
Agricola
Right arrow Articles by Moger, W. H.
Right arrow Articles by Murphy, P. R.

Biology of Reproduction, Vol 26, 422-428, Copyright © 1982 by Society for the Study of Reproduction

ARTICLES

Reevaluation of the effect of follicle-stimulating hormone on the steroidogenic capacity of the testis: the effects of neuraminidase- treated FSH preparations

WH Moger and PR Murphy

The ability of FSH treatment to increase the amount of androgen produced by the testis in response to maximum LH stimulation may be an effect of the LH contamination of the FSH preparations. To examine this question, 3 FSH preparations of different potencies and degrees of LH contamination or their neuraminidase-treated derivatives were administered to hypophysectomized immature rats for 5 days. The capacity of the testes to produce androgens in vitro was assessed at the end of the treatment period. Neuraminidase treatment reduces the in vivo activity of ovine and bovine FSH but does not alter the activity of ovine or bovine LH. Neuraminidase treatment of one FSH preparation (NH-bFSH-B1) did not reduce the ability of this FSH preparation to increase the response of the testis to LH stimulation in vitro. This suggests that the considerable LH contamination of the NIH-bFSH-B1 may be responsible for its effect. However, neuraminidase treatment of 2 more highly purified FSH preparations (bFSH-199C and NIH-oFSH-S13) abolished or greatly reduced the ability of these preparations to increase testicular weight and the response to LH in vitro. It is concluded that the ability of highly-purified FSH preparations to increase the amount of androgen produced by the testis is due to FSH activity and not the contaminating LH.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
O. Levalle, C. Zylbersztein, S. Aszpis, D. Aquilano, C. Terradas, M. Colombani, C. Aranda, and H. Scaglia
Recombinant Human Follicle-Stimulating Hormone Administration Increases Testosterone Production in Men, Possibly by a Sertoli Cell-Secreted Nonsteroid Factor
J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3973 - 3976.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by the Society for the Study of Reproduction.